Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Aug. 15 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National Cancer Centre

Trial Status: NA

Principal Investigator(s): Dr Ravindran Kanesvaran

Published by HT Digital Content Services with permission from Health Daily Digest....